Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 1266 | 11.96 |
09:34 ET | 2870 | 12.12 |
09:36 ET | 3462 | 12.16 |
09:38 ET | 6467 | 12.21 |
09:39 ET | 12148 | 12.37 |
09:41 ET | 20899 | 12.34 |
09:43 ET | 7700 | 12.07 |
09:45 ET | 2175 | 12.02 |
09:48 ET | 2516 | 12.13 |
09:50 ET | 4858 | 12.205 |
09:52 ET | 19706 | 12.25 |
09:54 ET | 12968 | 12.4 |
09:56 ET | 10188 | 12.42 |
09:57 ET | 6239 | 12.46 |
09:59 ET | 7941 | 12.5 |
10:01 ET | 4069 | 12.34 |
10:03 ET | 5581 | 12.2 |
10:06 ET | 1471 | 12.18 |
10:08 ET | 750 | 12.23 |
10:10 ET | 9640 | 12.28 |
10:12 ET | 4685 | 12.37 |
10:14 ET | 8011 | 12.35 |
10:15 ET | 2665 | 12.41 |
10:17 ET | 6012 | 12.38 |
10:19 ET | 2000 | 12.36 |
10:21 ET | 3474 | 12.3 |
10:24 ET | 400 | 12.17 |
10:26 ET | 2058 | 12.205 |
10:28 ET | 204 | 12.17 |
10:30 ET | 200 | 12.21 |
10:32 ET | 1417 | 12.29 |
10:33 ET | 2728 | 12.34 |
10:35 ET | 6894 | 12.32 |
10:37 ET | 4500 | 12.27 |
10:39 ET | 600 | 12.24 |
10:42 ET | 2715 | 12.26 |
10:44 ET | 800 | 12.3 |
10:46 ET | 300 | 12.34 |
10:48 ET | 100 | 12.335 |
10:50 ET | 1000 | 12.35 |
10:51 ET | 583 | 12.34 |
10:53 ET | 1360 | 12.31 |
10:55 ET | 3392 | 12.31 |
10:57 ET | 1196 | 12.34 |
11:02 ET | 7476 | 12.45 |
11:04 ET | 4615 | 12.37 |
11:06 ET | 2475 | 12.48 |
11:08 ET | 1358 | 12.47 |
11:09 ET | 6501 | 12.6 |
11:11 ET | 2275 | 12.59 |
11:13 ET | 648 | 12.53 |
11:15 ET | 750 | 12.535 |
11:18 ET | 1050 | 12.52 |
11:20 ET | 5118 | 12.48 |
11:22 ET | 200 | 12.52 |
11:24 ET | 46324 | 12.765 |
11:26 ET | 3215 | 12.66 |
11:27 ET | 2439 | 12.62 |
11:29 ET | 2083 | 12.615 |
11:31 ET | 2616 | 12.575 |
11:33 ET | 5052 | 12.625 |
11:36 ET | 1898 | 12.63 |
11:38 ET | 15724 | 12.735 |
11:40 ET | 300 | 12.73 |
11:42 ET | 3527 | 12.72 |
11:44 ET | 7978 | 12.655 |
11:45 ET | 622 | 12.65 |
11:47 ET | 600 | 12.68 |
11:49 ET | 2200 | 12.64 |
11:51 ET | 9100 | 12.7 |
11:54 ET | 1200 | 12.72 |
11:56 ET | 25142 | 12.77 |
11:58 ET | 2354 | 12.73 |
12:00 ET | 6937 | 12.735 |
12:02 ET | 2968 | 12.8 |
12:03 ET | 500 | 12.79 |
12:05 ET | 5032 | 12.7271 |
12:07 ET | 1039 | 12.735 |
12:09 ET | 900 | 12.72 |
12:12 ET | 400 | 12.755 |
12:14 ET | 708 | 12.72 |
12:16 ET | 3900 | 12.61 |
12:18 ET | 311 | 12.61 |
12:20 ET | 13178 | 12.4741 |
12:21 ET | 2246 | 12.5075 |
12:23 ET | 1100 | 12.5099 |
12:25 ET | 211 | 12.4899 |
12:27 ET | 61750 | 12.49 |
12:30 ET | 800 | 12.42 |
12:32 ET | 3773 | 12.3996 |
12:34 ET | 4000 | 12.4236 |
12:36 ET | 1700 | 12.405 |
12:38 ET | 550 | 12.375 |
12:39 ET | 1900 | 12.21 |
12:41 ET | 1950 | 12.29 |
12:43 ET | 100 | 12.31 |
12:45 ET | 350 | 12.29 |
12:48 ET | 2438 | 12.16 |
12:50 ET | 3419 | 12.08 |
12:52 ET | 6976 | 12.1 |
12:54 ET | 2400 | 12.1931 |
12:56 ET | 400 | 12.18 |
12:57 ET | 850 | 12.18 |
12:59 ET | 300 | 12.21 |
01:01 ET | 1000 | 12.23 |
01:03 ET | 7259 | 12.275 |
01:06 ET | 400 | 12.275 |
01:08 ET | 2800 | 12.2 |
01:10 ET | 600 | 12.22 |
01:12 ET | 700 | 12.2 |
01:14 ET | 782 | 12.25 |
01:15 ET | 2048 | 12.2 |
01:17 ET | 1815 | 12.22 |
01:19 ET | 1600 | 12.18 |
01:21 ET | 1400 | 12.17 |
01:24 ET | 400 | 12.175 |
01:26 ET | 400 | 12.17 |
01:28 ET | 500 | 12.2 |
01:30 ET | 1200 | 12.175 |
01:32 ET | 2500 | 12.26 |
01:33 ET | 1202 | 12.22 |
01:35 ET | 100 | 12.25 |
01:37 ET | 100 | 12.21 |
01:39 ET | 2100 | 12.225 |
01:42 ET | 200 | 12.19 |
01:44 ET | 500 | 12.2 |
01:46 ET | 3000 | 12.22 |
01:48 ET | 3400 | 12.29 |
01:50 ET | 581 | 12.3 |
01:51 ET | 1048 | 12.37 |
01:53 ET | 300 | 12.32 |
01:55 ET | 400 | 12.33 |
01:57 ET | 500 | 12.3 |
02:00 ET | 600 | 12.31 |
02:02 ET | 300 | 12.34 |
02:04 ET | 793 | 12.345 |
02:08 ET | 400 | 12.35 |
02:09 ET | 1291 | 12.33 |
02:11 ET | 400 | 12.35 |
02:13 ET | 1378 | 12.4 |
02:15 ET | 2150 | 12.49 |
02:18 ET | 6070 | 12.45 |
02:22 ET | 1400 | 12.31 |
02:24 ET | 676 | 12.28 |
02:27 ET | 400 | 12.33 |
02:29 ET | 500 | 12.29 |
02:31 ET | 1546 | 12.34 |
02:33 ET | 600 | 12.3403 |
02:36 ET | 450 | 12.34 |
02:38 ET | 954 | 12.33 |
02:40 ET | 796 | 12.3 |
02:42 ET | 200 | 12.31 |
02:44 ET | 750 | 12.31 |
02:45 ET | 2200 | 12.32 |
02:47 ET | 1107 | 12.315 |
02:49 ET | 410 | 12.35 |
02:51 ET | 1500 | 12.36 |
02:54 ET | 950 | 12.39 |
02:56 ET | 300 | 12.39 |
02:58 ET | 1000 | 12.39 |
03:00 ET | 2000 | 12.34 |
03:02 ET | 700 | 12.35 |
03:03 ET | 400 | 12.33 |
03:05 ET | 2718 | 12.3 |
03:07 ET | 1746 | 12.3396 |
03:09 ET | 3024 | 12.415 |
03:12 ET | 600 | 12.37 |
03:14 ET | 800 | 12.34 |
03:16 ET | 700 | 12.32 |
03:18 ET | 1065 | 12.34 |
03:20 ET | 962 | 12.38 |
03:21 ET | 4817 | 12.34 |
03:23 ET | 1107 | 12.3 |
03:25 ET | 1243 | 12.3 |
03:27 ET | 700 | 12.32 |
03:30 ET | 1902 | 12.3 |
03:32 ET | 1005 | 12.31 |
03:34 ET | 1230 | 12.31 |
03:36 ET | 1633 | 12.29 |
03:38 ET | 2509 | 12.32 |
03:39 ET | 2097 | 12.3114 |
03:41 ET | 2956 | 12.33 |
03:43 ET | 754 | 12.33 |
03:45 ET | 1700 | 12.33 |
03:48 ET | 300 | 12.35 |
03:50 ET | 8837 | 12.395 |
03:52 ET | 2208 | 12.39 |
03:54 ET | 2762 | 12.39 |
03:56 ET | 5715 | 12.3 |
03:57 ET | 8549 | 12.36 |
03:59 ET | 14550 | 12.37 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 411.6M | -3.5x | --- |
LENZ Therapeutics Inc | 406.3M | -1.0x | --- |
Replimune Group Inc | 404.5M | -2.1x | --- |
Neurogene Inc | 394.2M | -6.4x | --- |
PepGen Inc | 430.8M | -4.2x | --- |
Terns Pharmaceuticals Inc | 380.9M | -4.7x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $411.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.